Myelodysplastic syndromes (MDS) represent a clinically heterogeneous group of disorders with challenging unmet therapeutic needs. At the 20th Congress of the European Hematology Association (EHA), Valeria Santini, MD, of the University of Florence, Florence, Italy, discusses emerging agents for the treatment of patients with MDS, including transforming growth factor-beta inhibitors, thrombopoietic agents and targets of mutant IDH2.
Get great new content delivered to your inboxSign up
By choosing to continue, you are confirming that you are a healthcare professional
Please enter your details if you would like to receive the latest Hemonc news and updates